COVID-19大流行期间重症哮喘生物治疗的安全性

IF 0.2 Q4 ALLERGY

Alergologia Polska - Polish Journal of Allergology Pub Date : 2021-01-01 DOI:10.5114/pja.2021.109381

Dorota Nawarycz, R. Pawliczak

{"title":"COVID-19大流行期间重症哮喘生物治疗的安全性","authors":"Dorota Nawarycz, R. Pawliczak","doi":"10.5114/pja.2021.109381","DOIUrl":null,"url":null,"abstract":"COVID-19 is an infectious disease that rapidly spread around the world and therefore is a challenge for treating chronic diseases, such as severe asthma. According to the guidelines of various health organizations, biological treatment in patients with severe asthma should be continued. The aim of this study was to evaluate the information we have gathered so far about safety of biological treatment of severe asthma during the COVID-19 pandemic. We analyzed data involving omalizumab, reslizumab, mepolizumab, benralizumab and dupilumab coming from case studies, surveys, single-center and multicenter studies, and review articles as well. The study focuses on risks of asthmatic patients' deterioration during COVID-19 and the severity of the infection itself. As a result, we learned that there is no strong evidence for asthma exacerbations in patients infected with COVID-19 while on their biological treatment course. Biological therapy can be safely used in patients with severe asthma, as long as all the precautions and the individual evaluation are provided.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":"8 1","pages":"134-138"},"PeriodicalIF":0.2000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety of biological treatment of severe asthma during the COVID-19 pandemic\",\"authors\":\"Dorota Nawarycz, R. Pawliczak\",\"doi\":\"10.5114/pja.2021.109381\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"COVID-19 is an infectious disease that rapidly spread around the world and therefore is a challenge for treating chronic diseases, such as severe asthma. According to the guidelines of various health organizations, biological treatment in patients with severe asthma should be continued. The aim of this study was to evaluate the information we have gathered so far about safety of biological treatment of severe asthma during the COVID-19 pandemic. We analyzed data involving omalizumab, reslizumab, mepolizumab, benralizumab and dupilumab coming from case studies, surveys, single-center and multicenter studies, and review articles as well. The study focuses on risks of asthmatic patients' deterioration during COVID-19 and the severity of the infection itself. As a result, we learned that there is no strong evidence for asthma exacerbations in patients infected with COVID-19 while on their biological treatment course. Biological therapy can be safely used in patients with severe asthma, as long as all the precautions and the individual evaluation are provided.\",\"PeriodicalId\":7469,\"journal\":{\"name\":\"Alergologia Polska - Polish Journal of Allergology\",\"volume\":\"8 1\",\"pages\":\"134-138\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alergologia Polska - Polish Journal of Allergology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/pja.2021.109381\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pja.2021.109381","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

摘要

COVID-19是一种在世界各地迅速传播的传染病，因此对治疗严重哮喘等慢性疾病构成挑战。根据各卫生组织的指导方针，重症哮喘患者应继续进行生物治疗。本研究的目的是评估我们迄今收集到的关于COVID-19大流行期间严重哮喘生物治疗安全性的信息。我们分析了omalizumab、reslizumab、mepolizumab、benralizumab和dupilumab的数据，这些数据来自病例研究、调查、单中心和多中心研究以及综述文章。这项研究的重点是哮喘患者在COVID-19期间病情恶化的风险以及感染本身的严重程度。因此，我们了解到，在生物治疗过程中，没有强有力的证据表明感染COVID-19的患者哮喘会加剧。生物疗法可以安全地用于重度哮喘患者，只要提供所有注意事项和个体评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Safety of biological treatment of severe asthma during the COVID-19 pandemic

COVID-19 is an infectious disease that rapidly spread around the world and therefore is a challenge for treating chronic diseases, such as severe asthma. According to the guidelines of various health organizations, biological treatment in patients with severe asthma should be continued. The aim of this study was to evaluate the information we have gathered so far about safety of biological treatment of severe asthma during the COVID-19 pandemic. We analyzed data involving omalizumab, reslizumab, mepolizumab, benralizumab and dupilumab coming from case studies, surveys, single-center and multicenter studies, and review articles as well. The study focuses on risks of asthmatic patients' deterioration during COVID-19 and the severity of the infection itself. As a result, we learned that there is no strong evidence for asthma exacerbations in patients infected with COVID-19 while on their biological treatment course. Biological therapy can be safely used in patients with severe asthma, as long as all the precautions and the individual evaluation are provided.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alergologia Polska - Polish Journal of Allergology ALLERGY-

自引率

50.00%

发文量

期刊介绍： Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.